DE112005002742A5 - Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen - Google Patents

Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen Download PDF

Info

Publication number
DE112005002742A5
DE112005002742A5 DE112005002742T DE112005002742T DE112005002742A5 DE 112005002742 A5 DE112005002742 A5 DE 112005002742A5 DE 112005002742 T DE112005002742 T DE 112005002742T DE 112005002742 T DE112005002742 T DE 112005002742T DE 112005002742 A5 DE112005002742 A5 DE 112005002742A5
Authority
DE
Germany
Prior art keywords
prognosis
diagnosis
compounds
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE112005002742T
Other languages
English (en)
Other versions
DE112005002742B4 (de
Inventor
Günter KLÖPPEL
Jutta Lüttges
Holger Kalthoff
Ole Ammerpohl
Robert Grützmann
Christian Pilarsky
Hans-Detlev Saeger
Ingo Alldinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Dresden
Original Assignee
Technische Universitaet Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Dresden filed Critical Technische Universitaet Dresden
Publication of DE112005002742A5 publication Critical patent/DE112005002742A5/de
Application granted granted Critical
Publication of DE112005002742B4 publication Critical patent/DE112005002742B4/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE112005002742T 2004-08-31 2005-08-26 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen Expired - Fee Related DE112005002742B4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE200410042822 DE102004042822A1 (de) 2004-08-31 2004-08-31 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE102004042822.0 2004-08-31
PCT/DE2005/001527 WO2006024283A2 (de) 2004-08-31 2005-08-26 Verbindungen und methoden zur behandlung, diagnose und prognose bei pankreaserkrankungen

Publications (2)

Publication Number Publication Date
DE112005002742A5 true DE112005002742A5 (de) 2007-08-09
DE112005002742B4 DE112005002742B4 (de) 2008-05-21

Family

ID=35853531

Family Applications (2)

Application Number Title Priority Date Filing Date
DE200410042822 Withdrawn DE102004042822A1 (de) 2004-08-31 2004-08-31 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE112005002742T Expired - Fee Related DE112005002742B4 (de) 2004-08-31 2005-08-26 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE200410042822 Withdrawn DE102004042822A1 (de) 2004-08-31 2004-08-31 Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen

Country Status (2)

Country Link
DE (2) DE102004042822A1 (de)
WO (1) WO2006024283A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2009528291A (ja) 2006-02-27 2009-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア オキシステロール化合物及びヘッジホッグ経路
EP2052739A4 (de) * 2006-08-16 2010-01-06 Forerunner Pharma Res Co Ltd Mittel zur behandlung von krebs mit einem liganden für neuromedin-u-rezeptor 2 (fm4)-molekül als wirkstoff
US20100292090A1 (en) * 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
JP2010133705A (ja) * 2007-03-16 2010-06-17 Perseus Proteomics Inc 癌の診断薬及び治療薬
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
CA2707663C (en) 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
DE102010043541B4 (de) 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
WO2011151321A1 (en) * 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
EP2463657A1 (de) * 2010-12-13 2012-06-13 Université de Liège Biomarker, Verwendungen von Biomarkern und Verfahren zur Identifizierung von Biomarkern
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
EP2847206A4 (de) 2012-05-07 2016-01-20 Univ California Oxysterol-analogon oxy133 zur induktion von osteogenese und hedgehog-signalisierung sowie zur adipogenesehemmung
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102643443B1 (ko) 2012-11-13 2024-03-06 비온테크 에스이 클라우딘 발현 암 질환의 치료제
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102058996B1 (ko) 2013-04-17 2019-12-24 엘지전자 주식회사 췌장암 진단용 바이오마커, 이를 위한 컴퓨팅 장치 및 이의 제어 방법
AU2014259672A1 (en) 2013-05-02 2015-12-03 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
EP2997181A4 (de) * 2013-05-17 2017-04-12 National Health Research Institutes Verfahren zur prognostischen klassifizierung und behandlung von schilddrüsenkrebs
EP3011334A1 (de) * 2013-06-20 2016-04-27 The Trustees Of The University Of Pennsylvania Verfahren zur diagnose von bauchspeicheldrüsenkrebs
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
WO2020225426A1 (en) * 2019-05-08 2020-11-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Colorectal cancer screening examination and early detection method
CN110702923B (zh) * 2019-11-05 2022-12-27 南通大学附属医院 Gpr115基因在制备抗肺癌药物及其诊断试剂盒中的应用
CN111973744B (zh) * 2020-07-15 2022-07-01 北京大学深圳医院 Plce1-as2在乳腺癌中的应用
WO2023004460A1 (en) * 2021-07-28 2023-02-02 Hudson Institute of Medical Research Methods of detecting and/or diagnosing pancreatic cancer
WO2023133275A1 (en) * 2022-01-07 2023-07-13 Sanford Burnham Prebys Medical Discovery Institute Inhibition of glutaryl-coa dehydrogenase for the treatment of melanoma
CN114480399A (zh) * 2022-03-17 2022-05-13 江苏医药职业学院 降低CPB1基因表达的siRNA、重组载体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
EP2241636A1 (de) * 2002-03-13 2010-10-20 Genomic Health, Inc. Genexpressionsprofilierung in einer Biopsie unterzogenem Tumorgewebe
ES2320443T3 (es) * 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Also Published As

Publication number Publication date
DE102004042822A1 (de) 2006-03-16
DE112005002742B4 (de) 2008-05-21
WO2006024283A2 (de) 2006-03-09
WO2006024283A3 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602006016610D1 (de) Endoskop, behandlungsvorrichtung für ein endoskop und endoskopsystem
ATE493660T1 (de) Mittel und verfahren zur prognose oder diagnose von diabetes typ ii
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602006002756D1 (de) Manschette für Blutdruckmessgerät, Herstellungsverfahren hierfür und Blutdruckmessgerät
ATE526421T1 (de) Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602005007576D1 (de) Behandlungsvorrichtung für ein endoskop
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE502006005862D1 (de) Filterlage für einen, insbesondere konischen, wabenkörper zur abgasbehandlung und verfahren zur herstellung der filterlage
WO2007101063A3 (en) Treatment of development-related disorders
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE602006008588D1 (de) Verfahren zur vorbeugung und/oder behandlung vaginaler infektionen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
DE60333195D1 (de) Verfahren zur diagnose des myokardinfarktrisikos
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130301